U.S. markets close in 3 hours 13 minutes
  • S&P 500

    4,588.55
    +55.79 (+1.23%)
     
  • Dow 30

    35,389.67
    +361.02 (+1.03%)
     
  • Nasdaq

    14,586.88
    +246.62 (+1.72%)
     
  • Russell 2000

    2,098.03
    +35.24 (+1.71%)
     
  • Crude Oil

    87.25
    +0.29 (+0.33%)
     
  • Gold

    1,843.10
    -0.10 (-0.01%)
     
  • Silver

    24.70
    +0.47 (+1.96%)
     
  • EUR/USD

    1.1337
    -0.0010 (-0.09%)
     
  • 10-Yr Bond

    1.8360
    +0.0090 (+0.49%)
     
  • GBP/USD

    1.3635
    +0.0023 (+0.17%)
     
  • USD/JPY

    114.1130
    -0.2400 (-0.21%)
     
  • BTC-USD

    43,151.96
    +1,110.46 (+2.64%)
     
  • CMC Crypto 200

    1,025.86
    +30.60 (+3.07%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Better Buy: DexCom or Abbott Labs?

·5 min read
Better Buy: DexCom or Abbott Labs?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

When it comes to relatively stable healthcare growth stocks, DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) just might fit the bill. Worth around $61 billion, the continuous glucose monitor (CGM) specialist DexCom is small compared to medical device giant Abbott's market cap of $228 billion -- and it's no wonder why, because Abbott makes everything from CGMs to COVID tests and even surgical tools. Adria Cimino (Abbott Laboratories): Coronavirus testing offered Abbott a big boost last year.